MACA

Moringa Acquisition Corp Class A Ordinary Shares

MACA

Market cap $32.6M

Overview Fund Activity

Delisted

MACA was delisted on the 15th of August, 2024.

Back to rankings

About: Moringa Acquisition Corp is a blank check company.

Employees: 3

Financials Shell Companies

Financial journalist opinion

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

LONDON--(BUSINESS WIRE)---- $MACA #KRAS--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ: MACA), Silexion presents an interesting opportunity in the rapidly growing field of targeted cancer treatments, particularly in addressing the challenges of pancreati.

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

The combined company's shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 The combined company's shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clinical-stage, oncology-focused biotechnology company, that would result in Silexion becoming publicly listed on the Nasdaq. The business combination provides for Silexion's pre-transaction equity value to be $62.5 million, based on a $10 share price.

Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

See News Rankings

Charts implemented using Lightweight Charts™